Activist investor Bluebell takes stake in GSK
[ad_1]
(Reuters) – Activist investor Bluebell Capital Partners has taken a small stake in British pharmaceuticals group GlaxoSmithKline (NYSE:) in efforts to shake up top management, a Financial Times report said on Wednesday.
In a letter sent to GSK’s chairman Jonathan Symonds, Bluebell called for chief executive Emma Walmsley to reapply for her job as she would have “renewed credibility both internally and externally”, the FT report said.
GSK activist Elliott took a stake earlier in the year. This prompted a change of leadership at GSK.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.
[ad_2]